Axsome Therapeutics IncAXSM

Capital at risk.

About Axsome Therapeutics Inc
Ticker
info
AXSM
Trading on
info
NASDAQ
ISIN
info
US05464T1043
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Herriot Tabuteau M.D.
Headquarters
info
One World Trade Center, New York, NY, United States, 10007
Employees
info
683
Website
info
axsome.com
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It is also developing AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York.
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 17 analysts.

Average price target

info
$173.00
Sentiment analysis

-1.5

Extreme greed

+1.5

0.88

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Axsome Therapeutics Inc share?
Collapse

Axsome Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Axsome Therapeutics Inc have?
Collapse

Axsome Therapeutics Inc currently has 48.8M shares.

Does Axsome Therapeutics Inc pay dividends?
Collapse

No, Axsome Therapeutics Inc doesn't pay dividends.

What is Axsome Therapeutics Inc 52 week high?
Collapse

Axsome Therapeutics Inc 52 week high is $139.13.

What is Axsome Therapeutics Inc 52 week low?
Collapse

Axsome Therapeutics Inc 52 week low is $64.11.

What is the 200-day moving average of Axsome Therapeutics Inc?
Collapse

Axsome Therapeutics Inc 200-day moving average is $91.85.

Who is Axsome Therapeutics Inc CEO?
Collapse

The CEO of Axsome Therapeutics Inc is Dr. Herriot Tabuteau M.D..

How many employees Axsome Therapeutics Inc has?
Collapse

Axsome Therapeutics Inc has 683 employees.

What is the market cap of Axsome Therapeutics Inc?
Collapse

The market cap of Axsome Therapeutics Inc is $6.07B.

What is the P/E of Axsome Therapeutics Inc?
Collapse

The current P/E of Axsome Therapeutics Inc is null.

What is the EPS of Axsome Therapeutics Inc?
Collapse

The EPS of Axsome Therapeutics Inc is -$5.98.

What is the PEG Ratio of Axsome Therapeutics Inc?
Collapse

The PEG Ratio of Axsome Therapeutics Inc is 0.

What do analysts say about Axsome Therapeutics Inc?
Collapse

According to the analysts Axsome Therapeutics Inc is considered a buy.